Modulation of antibody effector function (Q37860624)

24 August 2017

1 reference

title

Modulation of antibody effector function (English)

1 reference

24 August 2017

1 reference

John R Desjarlais

1

1 reference

24 August 2017

Greg A Lazar

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 April 2011

1 reference

Experimental Cell Research

24 August 2017

published in

1 reference

24 August 2017

volume

317

1 reference

24 August 2017

issue

9

1 reference

24 August 2017

page(s)

1278-1285

1 reference

Optimization of Fc-mediated effector functions of monoclonal antibodies

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

FcγRs in health and disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Complement function in mAb-mediated cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Mechanisms of killing by anti-CD20 monoclonal antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Engineered antibody Fc variants with enhanced effector function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Engineered antibodies with increased activity to recruit complement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Modulation of the effector functions of a human IgG1 through engineering of its hinge region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Engineered therapeutic antibodies with improved effector functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Dual Functional Monoclonal Antibody PF-04605412 Targets Integrin α5β1 and Elicits Potent Antibody-Dependent Cellular Cytotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Identification of a receptor required for the anti-inflammatory activity of IVIG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Enhanced antibody half-life improves in vivo activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.018

10.1016/J.YEXCR.2011.03.018

7 January 2021

Identifiers

DOI

1 reference

24 August 2017

1 reference